INTRODUCTION
============

Alzheimer\'s disease (AD) is the most common form of dementia among the elderly,^[@r1]^ accounting for 35 to 80% of cases of dementia in these individuals.^[@r2]^ It is also the most frequent cause of dementia in the Brazilian elderly population.^[@r3]^ Characterized by progressive dementia,^[@r4]^ AD is a neurodegenerative disease whose definitive diagnosis cannot yet be established without histological analysis of the brain (biopsy or necropsy). The disease is associated with specific degeneration in brain tissue, especially in pyramidal neurons, with marked intracellular presence of neurofibrillary tangles (hyperphosphorylation of β-amyloid) - resulting from the abnormal metabolism of amyloid precursor protein (APP) - in the extracellular compartment, accompanied by other structural alterations such as granulovacuolar degeneration, dendritic atrophy and loss of neural synapses.^[@r5]^ Patients with AD may have limited access to memories that shape their self-awareness and self-image, resulting in a compromised sense of identity.^[@r6]^ Over the course of the disease, other symptoms may emerge, such as disorientation, mood swings, confusion, more severe memory deficits, behavioral changes, as well as difficulties speaking, swallowing, and walking.^[@r7]^

Traumatic brain injury (TBI) is a nondegenerative and noncongenital insult to the brain from an external mechanical force. It is associated with diminished or altered state of consciousness and it can lead to permanent or temporary impairment of cognitive, physical, and psychosocial functions.^[@r8]^ The most common causes of TBI are car crashes, falls, assaults and thefts, and accidents during recreational activity.^[@r9]^ It is considered a \"silent epidemic\",^[@r10]^ being the major cause of morbidity and mortality^[@r11]^ and leading cause of death and sequelae in children and young adults in western industrialized countries^[@r12]^. Annually, TBI affects around 10 million people, leading to death or hospitalization.^[@r13]^

The acceleration-deceleration mechanism, responsible for diffuse axonal injury (DAI), causes the fast rotational forces attributed to shear strain, damaging the axons.^[@r14]^ This mechanism often damages the lateral and ventral regions of the frontal and temporal lobes. Deficits in attention and memory, difficulty learning new information, solving problems and planning, and problems associated with impulsivity and self-control are common sequelae.^[@r2]^ Long-term memory is usually restored, but some individuals find it difficult to learn and retain new information. Working memory is often affected at different stages - coding, storage and retrieval. These changes have a significant impact on the social and professional reintegration of the individual.^[@r15]^

Although AD and DAI have different mechanisms of injury, complaints such as memory deficits and difficulty learning new information are common to both groups of patients. For the investigation of both, electroencephalographic (EEG) recording in awake-resting state condition is an ideal low-cost and non-invasive methodology. Indeed, EEG recording has a high temporal resolution (milliseconds) that provides an optimal investigational tool for the emerging features of brain physiology.^[@r9]^ EEG procedures are well-tolerated by patients, unaffected by task difficulty and are widely available in any country. They can be repeated over time without habituation effects.^[@r17]^

When compared to groups of normal elderly subjects, AD groups are characterized by high power widespread delta and theta rhythms, as well as by low power posterior alpha and/or beta rhythms.^[@r16]-[@r19]^ Moreover, EEG amplitude modulation analysis has been shown to be useful for characterizing AD progression from mild to moderate stages.^[@r20]^

The EEG immediately after TBI initially shows epileptiform activity,^[@r21]^ followed by suppressed cortical activity - which may last from seconds to about a minute.^[@r22]^ Many patients return to normal within an hour, while others continue to present focal or generalized slowing - which can last from weeks to a few months.^[@r23]^ The theta/alpha ratio increases after mild TBI and tends to return to normal within weeks to months.^[@r24]^ Quantitative EEG also shows an immediate reduction in the mean frequency of alpha and an increase in theta slow activity. These changes usually take weeks to months to resolve. Improvement is associated with a reduction in symptoms.^[@r23]^

Low-resolution brain electromagnetic tomography (LORETA) is a mathematical algorithm that estimates the sources of EEG recorded on the scalp^[@r25]^ and is widely used in EEG studies. New improved versions of LORETA have been developed such as Standardized low-resolution brain electromagnetic tomography (sLORETA) and Exact low resolution brain electromagnetic tomography (eLORETA). sLORETA^[@r26]^ and eLORETA^[@r27]^ have the same low spatial resolution, with zero localization error, but the eLORETA provides better localization of the signal source in the presence of noise.^[@r28]^

To establish the electroencephalographic differences in functional mechanisms between Alzheimer\'s disease and diffuse axonal injury patients, both with memory complaints, among other shared symptoms.

METHODS
=======

**Ethics statement.** This study was approved by the Ethics in Research Committee (CAPPesq) of the Clinicas Hospital School of Medicine, University of São Paulo. All recruited participants provided written consent.

**Inclusion criteria.** Elderly patients diagnosed with probable AD, as determined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer\'s disease and Related Disorders Association^[@r29]^ with CDR=1 or 2 and Mini-Mental State Examination (MMSE) scores from 13 to 29 - mild or moderate phase - were included. Subjects were recruited by the Cognitive Neurology and Behavior Group of the Neurology Department, University of São Paulo Medical School Hospital (FMUSP-HC). Patients who participated in this study had the diagnosis of AD for at least 6 months. The patients were not taking anticholinergic drugs.

Subjects aged 18 years or older diagnosed with mild/moderate (Rancho Los Amigos ≥5 and MMSE scores from 13 to 28) DAI in the chronic phase and that presented memory complaints were included. They were recruited by the Cognitive Rehabilitation Group after TBI in the Division of Neurology, Clinicas Hospital, School of Medicine, University of São Paulo. The subjects with DAI who participated in this study were examined in the chronic stage (≥6 months after TBI). Patients with DAI were diagnosed based on the following criteria:^[@r30]^

1.  A loss of consciousness from the time of injury that persisted beyond 6 h;

2.  No apparent hemorrhagic contusion on computed tomography (CT);

3.  The presence of white matter injury on MRI.

In addition, healthy adults with no memory complaints were recruited to serve as controls. Individuals of both sexes were included in the study. The instruments used for cognitive assessment in patients and adult controls were the MMSE, verbal fluency test (VF, animals category) and clock-drawing test (CDT). Demographic data and performance on screening tests are reported in the next section.

**Exclusion criteria.** Patients using medications that can modify the EEG record (such as antidepressant drugs, tricyclic compounds, nefazodone, benzodiazepines, lithium, neuroleptics) were excluded. Subjects with other neurological and/or psychiatric disorders, or that had suffered more than one TBI were also excluded from this study.

**EEG recordings and data acquisition.** EEG signals were recorded with a digital high-resolution 128-channel device (Brain Vision) using the International 10-10 system.^[@r17]^ Sampling frequency was 10000 Hz and impedance of all electrodes was maintained below 10 kΩ. The recordings were performed at resting state, with participants comfortably seated in a reclined chair for approximately 25 min. During this period, the subjects kept their eyes closed most of the time (20 minutes). When drowsiness was noticed, they were asked to open their eyes and this event was duly noted in the EEG recording. Two neurophysiologists, who are board certified, selected the EEG tracings for further analysis.

**EEG pre-processing.** The EEGLAB software package,^[@r31]^ which runs in the MATLAB (MathWorks^®^) software environment, was used to perform all pre-processing steps. All filtering was done in the zero-phase mode. First of all, the EEG was downsampled from 10000 Hz to 1000 Hz and once again to 400 Hz after lowpass filtering to 115 Hz using a 5^th^-order Chebyshev II filter. Subsequently, two Butterworth 4^th^-order filters were applied, one to eliminate power grid interference (60 Hz, notch) and the other to remove very slow fluctuations (0.4 Hz, highpass). Eyes-opening and closing events were identified, since analysis focused on the second eyes-closed moment onwards while everything before that was discarded. Average referencing was performed and the 128-channel EEG signal was divided into 4-second epochs. Epochs with strong artifacts (outside the ±450 µV range or with slope above 250 µV/50 ms) were eliminated. Finally, ocular and muscular artifacts were removed with the EEGLAB Independent Component Analysis (ICA) tool.^[@r31]^ After all these pre-processing steps, seventy 4-second epochs for each participant were stored in .txt format to serve as input EEG files to the LORETA-KEY software (<http://www.uzh.ch/keyinst/loreta>).

**EEG source localization.** eLORETA was used to analyze the cortical distribution of current source density. The head model of eLORETA and the electrode coordinates are based on the Montreal Neurological Institute average MRI brain map (MNI152).^[@r32]^ The solution space was limited to the cortical gray matter, including 6239 voxels with spatial resolution of 5 cubic mm. The eLORETA tomography has been previously used in several studies.^[@r18],[@r33],[@r34]^ Selected artifact-free EEG fragments were analyzed to calculate the eLORETA cortical current source density from 0.5 Hz to 30 Hz. The current source density of the eLORETA cortical functioning image was calculated for eight frequency bands: delta (1.5-6 Hz), theta (6.5-8 Hz), alpha 1 (8.5-10 Hz), alpha 2 (10.5-12 Hz), beta 1 (12.5-18 Hz), beta 2 (18.5-21 Hz), beta 3 (18.5-30 Hz) and omega - full-band (1.5-30 Hz).

**Statistical analysis.** Frequency tables and descriptive statistics were used to describe the profile of the sample. The Mann-Whitney U and Kruskal-Wallis tests were used to compare the continuous variables between two or three groups, respectively. Pearson\'s Chi-square test was used to compare the categorical variables between the diagnostic groups. For statistical analysis, the Social Package for Social Science (SPSS) version 20 by International Business Machines (IBM) was used. The significance level adopted for the statistical tests was 5%, i.e. a p-value \<0.05.

For the statistical analysis of current source density, the statistical nonparametric mapping method (SnPM)^[@r35]^ was used, available as a software tool in the LORETA-KEY package. The difference in cortical source localization between groups was assessed for each frequency band with voxel-by-voxel independent F-ratio-tests, based upon eLORETA log-transformed current source density power. Cortical voxels with significant differences were identified by means of a nonparametric randomization procedure, in the three-dimensional statistical mapping. The mean source power in each voxel and the distribution in the permutated values was compared, with threshold set at a 5% significance level. A total of 5000 data randomizations were used to determine the critical probability threshold values for the actually observed log F-ratio values, with correction for multiple comparisons across all voxels and frequencies.

RESULTS
=======

The final sample consisted of 17 control individuals, 20 patients with Alzheimer\'s disease and 19 patients with DAI. [Table 1](#t1){ref-type="table"} summarizes the relevant demographic data for the CTL, AD and DAI participants. [Table 2](#t2){ref-type="table"} summarizes the relevant clinical data and screening test results for the participants.

###### 

Demographic data in the subgroup of Alzheimer\'s disease, diffuse axonal injury and healthy control participants.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables           CTL                 AD                 DAI               Statistical analyses
  ------------------- ------------------- ------------------ ----------------- --------------------------------------------------------------------------------------------------------------------------------------------
  N                   17                  20                 19                 

  Gender              \-                  \-                 \-                p=0.765^[a](#TFN2){ref-type="table-fn"}^, 0.149^[b](#TFN3){ref-type="table-fn"}^, 0.224^[c](#TFN4){ref-type="table-fn"}^ (Chi-square test)

  Male                8                   11                 14                \-

  Female              9                   9                  5                 \-

  Age                 47.94 (±20.82 SE)   77.35 (±6.19 SE)   50 (±11.28 SE)    P\<0.001^[a](#TFN2){ref-type="table-fn"},[c](#TFN4){ref-type="table-fn"}^, 0.832^[b](#TFN3){ref-type="table-fn"}^\
                                                                               (Mann-Whitney U test)

  Education (years)   13.94 (±3.96 SE)    7.35 (±4.68 SE)    7.47 (±5.21 SE)   p\<0.001^[a](#TFN2){ref-type="table-fn"},[b](#TFN3){ref-type="table-fn"}^, 0.806^[c](#TFN4){ref-type="table-fn"}^\
                                                                               (Mann-Whitney U test)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CTL: control. AD: Alzheimer\'s disease. DAI: diffuse axonal injury.

CTL × AD;

CTL × DAI;

AD × DAI.

###### 

Performance on screening tests in the subgroup Alzheimer\'s disease, diffuse axonal injury and healthy control participants.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                  CTL                AD                 DAI                Statistical analyses
  -------------------------- ------------------ ------------------ ------------------ --------------------------------------------------------------------------------------------------------------------
  CDR                        \-                 1.25 (±0.55 SE)    \-                  

  Rancho los Amigos Scale    \-                 \-                 7 (±1.05 SE)       \-

  MMSE                       29 (±1.59 SE)      22.55 (±3.52 SE)   23.42 (±4.44 SE)   p\<0.001^[a](#TFN6){ref-type="table-fn"},[b](#TFN7){ref-type="table-fn"}^, 0.359^[c](#TFN8){ref-type="table-fn"}^\
                                                                                      (Mann-Whitney U test)

  Clock-drawing test         9.44 (±0.51 SE)    5.70 (±3.08 SE)    7.37 (±2.36 SE)    p\<0.001^[a](#TFN6){ref-type="table-fn"},[b](#TFN7){ref-type="table-fn"}^, 0.088^[c](#TFN8){ref-type="table-fn"}^\
                                                                                      (Mann-Whitney U test)

  Verbal fluency (animals)   19.75 (±4.36 SE)   11.15 (±4.68 SE)   10.58 (±4.07 SE)   p\<0.001^[a](#TFN6){ref-type="table-fn"},[b](#TFN7){ref-type="table-fn"}^, 0.799^[c](#TFN8){ref-type="table-fn"}^\
                                                                                      (Mann-Whitney U test)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CTL: control; AD: Alzheimer\'s disease; DAI: diffuse axonal injury;

CTL × AD;

CTL × DAI;

AD × DAI.

**EEG findings.** The mean alpha frequency peak was 10.23 Hz (±0.90 SE) for the CTL participants, 9.30 Hz (±0.72 SE) for the AD group and 9.73 Hz (±1.02 SE) for the DAI group. Statistical analysis (Mann-Whitney U test) was performed to test possible differences in the alpha frequency peak between the groups. A statistically significant difference was found between the CTL and AD groups (p\<0.05). No statistically significant difference was found between the CTL and DAI groups (p\>0.125) or between the AD and DAI groups (p\>0.136).

**eLORETA analysis.** The eLORETA analysis was performed with 32, 64 and 128 channels (10-20 and 10-10 system). On the comparison between CTL and AD groups, the analysis with 32 channels revealed differences in the theta and alpha2 bands. Brain structures containing voxels with statistically significant differences are shown in [Table 3](#t3){ref-type="table"} and in [Figure 1a](#f1){ref-type="fig"} and [1b](#f1){ref-type="fig"}. The analysis with 64 channels also revealed differences, but only in the alpha2 band. Brain structures in which voxels with statistically significant differences were found are shown in [Table 4](#t4){ref-type="table"} and in [Figure 1c](#f1){ref-type="fig"}.

###### 

Brain structures with statistically significant difference on eLORETA in comparison - CTL × AD (32-channel analysis).

  ------------------ --- ------------------
  **Theta band**         
  Lobe                   Brodmann areas
  Frontal                4
  Parietal               1, 2, 3, 40
  **Alpha 2 band**       
  Lobe                   Brodmann areas
  Parietal               5, 7, 19, 31, 40
  Frontal                5, 31
  Limbic                 23, 31
  Occipital              7, 18, 19, 31
  ------------------ --- ------------------

###### 

Brain structures with statistically significant difference for alpha 2 band on eLORETA (64-channel analysis) - CTL × AD.

  -------- --- ----------------
  Lobe         Brodmann areas
  Limbic       23, 31
  -------- --- ----------------

Figure 1Representation of brain areas with statistically significant differences in comparison CTL × AD for theta band on 32-channel analysis (CTL\<AD) \[A\], for alpha 2 band on 32-channel analysis (CTL\>AD) \[B\] and for alpha 2 band on 64-channel analysis (CTL\>AD) \[C\].

On the comparison between CTL and DAI groups, the analysis with 32 channels showed differences only in the theta band. The brain structures in which voxels with statistically significant differences were found are given in [Table 5](#t5){ref-type="table"} and [Figure 2a](#f2){ref-type="fig"}. The 64-channel analysis also showed significant differences only in the theta band ([Table 5](#t5){ref-type="table"}, [Figure 2b](#f2){ref-type="fig"}).

###### 

Brain structures with statistically significant difference for theta band on eLORETA in comparison - CTL × DAI.

  ----------------- ----------------------------------------
  **32 channels**   
  Lobe              Brodmann areas
  Limbic lobe       19, 23, 27, 28, 29, 30, 31, 34, 35, 36
  Occipital         17, 18, 19, 30, 31
  Sub-lobar         13
  Temporal          41
  **64 channels**   
  Lobe              Brodmann areas
  Limbic lobe       23, 27, 29, 30
  Occipital         17, 18, 19, 30
  Sub-lobar         13
  ----------------- ----------------------------------------

Figure 2Representation of brain areas with statistically significant differences on comparison CTL × DAI for theta band on 32-channel analysis (CTL\<DAI) \[A\], and for theta band on 64-channel analysis (CTL\<DAI).

No differences were found between the CTL and AD groups or the CTL and DAI groups for the 128-channel analysis. Also, there were no statistical differences between AD and DAI groups at any of the settings (32, 64 or 128 channels).

DISCUSSION
==========

Although AD and DAI patients differed in age and schooling, they had the same cognitive impairment profile, since they had many common symptoms. For this reason, we sought to compare them and determine electroencephalographic differences.

Regarding gender, no significant statistical differences were found between the CTL and AD groups or CTL and DAI groups. The DAI group had a higher number of males than the AD group, with a statistically significant difference. The literature shows that 2-3 times more men are affected by TBI than women.

The mean age of the DAI group was lower than that of the CTL group and the AD group. This was expected since TBI tends to affect younger adults whereas AD occurs mostly in elderly individuals.

The diagnosis of most cognitive disorders is clinical, but the EEG plays a role in the evaluation, classification and follow-up of these disorders. It is an important method for evaluation of cortical processing and physiological changes.^[@r36]^ A decrease in alpha and beta rhythms and increase in delta and theta frequencies are related to brain lesions and cognitive decline.^[@r37]^ Babiloni et al. (2004), using LORETA, showed that individuals with mild AD had a significant reduction in alpha 1 activity compared to healthy elderly subjects in all areas, particularly in the central, parietal, temporal and limbic areas.^[@r38]^ Gianotti et al. (2006) failed to find differences between mild/moderate AD groups and controls for the alpha 1 band. However, differences were observed for the alpha 2 band, which decreased in the occipital area more prominently in the right hemisphere.^[@r39]^ Babiloni et al. (2009) studied a group of individuals with mild cognitive impairment (MCI) and AD and found a reduction in alpha 1 activity in the occipital, temporal and parietal areas.^[@r40]^ Canuet et al. (2012) found differences between groups, using the eLORETA method, only for the alpha 1 band in the parieto-occipital region, mainly in the right pre-cuneus region.^[@r28]^ Caso et al. (2012), based on spectral analysis and sLORETA, observed that patients with AD, in comparison with controls, had lower activity for fast frequencies (alpha 1, alpha 2, beta 1 and beta 2) in the central and posterior regions.^[@r41]^ Babiloni et al. (2016) studied controls, patients with Parkinson\'s disease and with AD. Using LORETA, they observed that, relative to controls, patients with AD had lower alpha 1 activity in the central, parietal, occipital and temporal areas and less alpha 2 activity in the parietal and occipital areas.^[@r42]^

Our literature search found no papers using LORETA analysis in patients with DAI. Indeed, there is scant literature involving TBI and LORETA. Tomkins et al. (2011) found, using sLORETA, that TBI patients had slower delta waves than controls.^[@r43]^ The study of Corradini and Persinger (2013) used sLORETA and revealed a decrease in para-hippocampal electrical activity and in regions adjacent to the temporal lobe in individuals with mild TBI.^[@r44]^

In our study, no differences were found between the AD and DAI groups for any EEG rhythm in any configuration (32, 64 or 128 channels). One possible explanation for this is that, although the mechanisms of injury differ in the two diseases, there are many similarities in their neuroanatomy and physiology, which leads the patients to present similar symptoms. At the beginning of AD, the main characteristic of clinical features is episodic memory impairment, i.e., the patient has difficulty remembering recent events and conversations, repeats questions and stories, and has trouble finding personal objects.^[@r45]^ Decreased autobiographical memory, decreased ability to learn new information as quickly as before the TBI, less proficiency to remember faces of new acquaintances, and delayed task execution after rapid or new visual presentations, are common complaints among post-TBI patients,^[@r44]^ especially in DAI^[@r9]^.

The first pathological link between a single TBI and AD was the observation that β-amyloid plaques are present in up to 30% of patients dying in the acute phase of TBI.^[@r46]^ APP can be found accumulated in damaged axons within 2 hours after injury.^[@r47]^ Several studies have identified that the history of a single TBI is an epigenetic risk factor for the later development of clinical syndromes of cognitive impairment, such as AD.^[@r48]^ The activation of posterior and medial portions of the parietal-occipital cortex (covering the cuneus and precuneus) has been reported with considerable consistency in PET and functional MRI studies during memory tasks,^[@r49]^ specifically for success in memory recall. The onset of amnestic syndromes is related to damage in portions of the medial temporal cortex, including the hippocampus and para-hippocampal gyrus.^[@r50]^

The onset of amnestic syndromes is related to damage in portions of the medial temporal cortex, including the hippocampus and para-hippocampal gyrus (Zola-Morgan et al., 1986). At the beginning of AD, the main characteristic of the clinical feature is episodic memory impairment.

There is a pathological link between a single TBI and AD, and it is well established that TBI patients have a higher risk for developing dementia in the future. Thus, the objective of the present study was to ascertain whether these groups had similarities in EEG.

Our analyzes have shown that with fewer channels, the resolution of LORETA is improved, since a channel is responsible for a larger portion of the scalp. For this reason, the analysis using 32 channels revealed more voxels with statistical differences between the groups.

Limitations of the study include the sample size and cross-sectional methodology employed, since patients were not followed during disease progression. It should be emphasized that this study provides contributions to the national literature, since the line of research involving cognitive electroencephalography is scarce. We found no articles comparing the group of Alzheimer\'s disease and diffuse axonal injury in the literature with regard to electroencephalographic profile. In fact, papers investigating diffuse axonal injury are very scarce. The use of the LORETA methodology is restricted to a few research groups and existing studies generally compare dementia x controls, or two types of dementia. We found no articles involving patients with traumatic brain injury and comparing them with dementia patients.

In conclusion, our findings showed a neurofunctional similarity between AD and DAI, and that the two groups differed in relation to the controls, which was expected, since it is a comparison between pathology and normality. This neurofunctional similarity helps to understand the functionality of these diseases - our results show that the areas involved in memory and learning are compromised in both pathologies and this knowledge can be extrapolated to studies aimed at the treatment of these conditions. Drugs known to prevent memory decline in Alzheimer\'s disease could also be used in diffuse axonal injury patients. Also, these findings could pave the way for the use of drugs that are commonly used in the treatment of AD in patients with DAI.

Further studies on the physiology of these diseases, from an electroencephalographic perspective in a greater number of individuals are necessary, and it is also important to correlate the electroencephalographic findings and cognitive performance of patients.
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